Patricia Campos-Bedolla

Dr. Patricia Campos-Bedolla

Unidad de Investigación Médica en Enfermedades Neurológicas, Hospital de Especialidades, Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Archives of Medical Research
Verified
Journal Article
Closed access
PCPatricia Campos-Bedolla
Patricia Campos-Bedolla
FWFruzsina R. Walter
Fruzsina R. Walter
Szilvia VeszelkaSzilvia Veszelka
Szilvia Veszelka
Maria DeliMaria Deli
Maria Deli

1 May 2001 in Biophysical Journal
Verified
Journal Article
Closed access
IQIvan Quesada
Ivan Quesada
WCWei-Chun Chin
Wei-Chun Chin
JSJordan Steed
Jordan Steed
PCPatricia Campos-Bedolla
Patricia Campos-Bedolla
PVPedro Verdugo
Pedro Verdugo

10 February 2020 in Fluids and Barriers of the CNS
Verified
Journal Article
Open access
PDF file
LBLilla Barna
Lilla Barna
Fruzsina WalterFruzsina Walter
Fruzsina Walter
AHAndrás Harazin
András Harazin
ABAlexandra Bocsik
Alexandra Bocsik
AKAndrás Kincses
András Kincses
Maria DeliMaria Deli
Maria Deli
Background: Excitotoxicity is a central pathological pathway in many neurological diseases with blood–brain barrier (BBB) dysfunction. Kainate, an exogenous excitotoxin, induces epilepsy and BBB damage in animal models, but the direct effect of kainate on brain endothelial cells has not been studied in detail. Our aim was to examine the direct effects of kainate on cultured cells of the BBB and to test three anti-inflammatory and antioxidant drugs used in clinical practice, simvastatin, edaravone and dexamethasone, to protect against kainate-induced changes. Methods: Primary rat brain endothelial cell, pericyte and astroglia cultures were used to study cell viability by impedance measurement. BBB permeability was measured on a model made from the co-culture of the three cell types. The production of nitrogen monoxide and reactive oxygen species was followed by fluorescent probes. The mRNA expression of kainate receptors and nitric oxide synthases were studied by PCR. Results: Kainate damaged brain endothelial cells and made the immunostaining of junctional proteins claudin-5 and zonula occludens-1 discontinuous at the cell border indicating the opening of the barrier. The permeability of the BBB model for marker molecules fluorescein and albumin and the production of nitric oxide in brain endothelial cells were increased by kainate. Simvastatin, edaravone and dexamethasone protected against the reduced cell viability, increased permeability and the morphological changes in cellular junctions caused by kainate. Dexamethasone attenuated the elevated nitric oxide production and decreased the inducible nitric oxide synthase (NOS2/iNOS) mRNA expression increased by kainate treatment. Conclusion: Kainate directly damaged cultured brain endothelial cells. Simvastatin, edaravone and dexamethasone protected the BBB model against kainate-induced changes. Our results confirmed the potential clinical usefulness of these drugs to attenuate BBB damage.

16 March 2022 in Epilepsia Open
Verified
Journal Article
Open access
PCPatricia Campos-Bedolla
Patricia Campos-Bedolla
IFIris Angélica Feria-Romero
Iris Angélica Feria-Romero
SOSandra Orozco-Suárez
Sandra Orozco-Suárez
More than one‐third of people with epilepsy develop drug‐resistant epilepsy (DRE). Different hypotheses have been proposed to explain the origin of DRE. Accumulating evidence suggests the contribution of neuroinflammation, modifications in the integrity of the blood‐brain barrier (BBB), and altered immune responses in the pathophysiology of DRE. The inflammatory response is mainly due to the increase of cytokines and related molecules; these molecules have neuromodulatory effects that contribute to hyperexcitability in neural networks that cause seizure generation. Some patients with DRE display the presence of autoantibodies in the serum and mainly cerebrospinal fluid. These patients are refractory to the different treatments with standard antiseizure medications (ASMs), and they could be responding well to immunomodulatory therapies. This observation emphasizes that the etiopathogenesis of DRE is involved with immunology responses and associated long‐term events and chronic inflammation processes. Furthermore, multiple studies have shown that functional polymorphisms as risk factors are involved in inflammation processes. Several relevant polymorphisms could be considered risk factors involved in inflammation‐related DRE such as receptor for advanced glycation end products (RAGE) and interleukin 1β (IL‐1β). All these evidences sustained the hypothesis that the chronic inflammation process is associated with the DRE. However, the effect of the chronic inflammation process should be investigated in further clinical studies to promote the development of novel therapeutics useful in treatment of DRE.

11 January 2010 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
PSP. Segura
P. Segura
MVM. H. Vargas
M. H. Vargas
GCG. Córdoba‐Rodríguez
G. Córdoba‐Rodríguez
JCJ. Chávez
J. Chávez
JAJ. L. Arreola
J. L. Arreola
LMLuis M Montaño
Luis M Montaño

1 February 1997 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
PCPatricia Campos-Bedolla
Patricia Campos-Bedolla
MCMaría G. Campos
María G. Campos
AVAntonio Valencia-Sánchez
Antonio Valencia-Sánchez
HPHéctor Ponce-Monter
Héctor Ponce-Monter
CUCarmen Uribe
Carmen Uribe
JCJ. Calderón
J. Calderón